Study for treatment of newly diagnosed high risk multiple myeloma (HRMM)
Primary disease category: Cancer
Secondary disease categories: Myeloma
Sponsor: Southwest Oncology Group
Protocol number: S1211
Projected enrollment dates: January 2014 to December 2017
Official study title: A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide with or without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)
External link(s):
UA Cancer Center Website
ClinicalTrials.gov page:
http://www.clinicaltrials.gov/show/NCT01668719